文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

建立去势抵抗性前列腺癌移植瘤模型。

Development of a castrate resistant transplant tumor model of prostate cancer.

机构信息

Roswell Park Cancer Institute, Genitourinary Program, Grace Cancer Drug Center, Buffalo, New York, USA.

出版信息

Prostate. 2012 May 1;72(6):587-91. doi: 10.1002/pros.21465. Epub 2011 Jul 27.


DOI:10.1002/pros.21465
PMID:21796655
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3298731/
Abstract

BACKGROUND: Currently, limited mouse models that mimic the clinical course of castrate resistant prostate development currently exist. Such mouse models are urgently required to conduct pre-clinical studies to assist in the understanding of disease progression and the development of rational therapeutic strategies to treat castrate resistant prostate cancer. METHODS: Wild type intact FVB male mice were injected by subcutaneous injection with Myc-CaP cells to establish androgen sensitive Myc-CaP tumors. Tumor bearing mice were castrated and resulting tumors serially passaged in pre-castrated FVB male mice to produce a bone fide Myc-CaP castrate resistant tumor. RESULTS: Immunohistochemical analysis revealed that initial androgen sensitive Myc-CaP tumors had strong nuclear transcriptional active androgen receptor expression, as indicated by marked c-MYC staining and were highly proliferative. Castration of tumor bearing animals resulted in cytoplasmic relocation of androgen receptor concurrent with loss of transcriptional activity and tumor proliferation. Serial passaging of castrate refractory Myc-CaP in pre-castrated male FVB mice resulted in the development of a bona fide castrate resistant Myc-CaP tumor which pheno-copied the original androgen sensitive parental Myc-CaP tumor. CONCLUSIONS: Developing a murine castrate transplant resistant tumor model that mimics the clinical course of human castrate resistant prostate cancer will create better opportunities to understand the development of castrate resistant prostate cancer and also allow for more rapid pre-clinical studies to stratify rational novel therapies for this lethal form of prostate cancer.

摘要

背景:目前,能够模拟去势抵抗性前列腺发展临床过程的有限的小鼠模型仍然存在。迫切需要此类小鼠模型来进行临床前研究,以帮助了解疾病进展,并制定合理的治疗策略来治疗去势抵抗性前列腺癌。

方法:通过皮下注射 Myc-CaP 细胞,向野生型完整 FVB 雄性小鼠注射,以建立雄激素敏感的 Myc-CaP 肿瘤。将荷瘤小鼠去势,并将产生的肿瘤连续传代至预先去势的 FVB 雄性小鼠中,以产生真正的 Myc-CaP 去势抵抗性肿瘤。

结果:免疫组织化学分析显示,初始雄激素敏感的 Myc-CaP 肿瘤具有强烈的核转录活性雄激素受体表达,如强烈的 c-MYC 染色和高度增殖所表明的。荷瘤动物去势导致雄激素受体的细胞质易位,同时丧失转录活性和肿瘤增殖。在预先去势的雄性 FVB 小鼠中连续传代去势抵抗性 Myc-CaP 导致了真正的去势抵抗性 Myc-CaP 肿瘤的发展,该肿瘤表型与原始雄激素敏感的 Myc-CaP 亲本肿瘤相似。

结论:开发一种能够模拟人类去势抵抗性前列腺癌临床过程的小鼠去势移植抵抗性肿瘤模型,将为更好地了解去势抵抗性前列腺癌的发展提供机会,并允许更快速地进行临床前研究,为这种致命形式的前列腺癌分层合理的新型治疗方法。

相似文献

[1]
Development of a castrate resistant transplant tumor model of prostate cancer.

Prostate. 2011-7-27

[2]
Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.

Clin Cancer Res. 2013-8-13

[3]
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.

Cancer Res. 2005-12-15

[4]
Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.

Cancer Res. 2008-12-1

[5]
Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.

PLoS One. 2014-7-29

[6]
Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.

PLoS One. 2013-1-11

[7]
Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.

Oncogene. 2010-9-6

[8]
Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.

PLoS One. 2012-1-17

[9]
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.

J Immunother Cancer. 2023-5

[10]
ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.

Carcinogenesis. 2012-1-9

引用本文的文献

[1]
Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer.

Front Immunol. 2025-5-22

[2]
Mediator kinase inhibition reverses castration resistance of advanced prostate cancer.

J Clin Invest. 2024-3-28

[3]
Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment.

Clin Cancer Res. 2021-6-1

[4]
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.

Br J Cancer. 2020-9

[5]
Loss of Myeloid BMPR1a Alters Differentiation and Reduces Mouse Prostate Cancer Growth.

Front Oncol. 2020-4-7

[6]
Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer.

Am J Clin Exp Urol. 2019-8-25

[7]
Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.

J Immunother Cancer. 2019-8-14

[8]
Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation.

Neoplasia. 2018-8-15

[9]
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer.

J Vis Exp. 2018-3-6

[10]
Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.

Cancer Immunol Res. 2017-10-19

本文引用的文献

[1]
Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors.

Horm Cancer. 2010-2

[2]
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.

Blood. 2009-7-9

[3]
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Science. 2009-5-8

[4]
The current state of preclinical prostate cancer animal models.

Prostate. 2008-5-1

[5]
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.

Cancer Res. 2007-7-1

[6]
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.

Proc Natl Acad Sci U S A. 2007-5-8

[7]
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.

Cancer Res. 2005-12-15

[8]
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

J Clin Oncol. 2005-11-10

[9]
Molecular determinants of resistance to antiandrogen therapy.

Nat Med. 2004-1

[10]
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

Cancer Cell. 2003-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索